Abstract
Introduction
Endometriosis is a chronic estrogen and progestogen responsive inflammatory condition defined by the presence of glands and stroma, which affects about 6-10% of women of reproductive age [1] .
Endometriosis is distinguished in three different phenotypes: ovarian endometrioma, superficial peritoneal endometriosis, and deep infiltrating endometriosis (DIE). Clinically, endometriosis can cause both pain symptoms (dysmenorrhea, deep dyspareunia, chronic pelvic pain and dyschezia) and infertility [2] . The surgical excision of endometriotic implants improves pain symptoms, but it may be associated with intestinal, urological and vascular complications. Furthermore, endometriosis-related pain may recur after surgery and patients may not accept a second operation.
In addition, some patients desire to delay or avoid surgery preferring a long-term medical therapy to control their symptoms [3] .
Medical treatment of endometriosis acts inducing decidualization and eventually atrophy within the hormonally dependent ectopic endometrium [4] . It aims to ameliorate pain symptoms as long-term therapy in women who do not undergo surgery. Moreover, it is controversial its role in preventing the postsurgical recurrences of implants, which has been demonstrated in short-term studies for ovarian endometriomas [5] . Differently, hormonal therapies used to treat endometriosis have no role in improving endometriosis-related infertility [6] . The choice of most appropriate therapy is based on intensity of pain, age, desire to conceive, cost, route of administration and impact of the endometriosis on work capacity, sexual function and quality of life (QoL) of each patient [7] .
Traditionally combined oral contraceptive (COC) pills have been the first-line treatment for patients with endometriosis, but currently progestins are increasingly and successfully employed as monotherapy, being efficacious and well tolerated [8, 9, 10] . This review aims to summarize the pharmacokinetic (PK) and the clinical efficacy of progestins available for the medical treatment of endometriosis.
A literature search was performed to find all the published studies evaluating PK and clinical efficacy of progestins for the treatment of endometriosis from inception until December 2017. The A c c e p t e d M a n u s c r i p t following electronic databases were used: Medline, PubMed, Embase, Science Citation Index via Web of Science, and the Cochrane Library. The following search terms were used: 'endometriosis' alone or in combination with 'progestin', 'medical therapy', 'pregnanes', 'estranes', 'gonanes' 'norethindrone', 'cyproterone', 'desogestrel,'etonogestrel' 'medroxyprogesterone', 'dienogest' 'levonorgestrel-intrauterine device'. All pertinent articles were carefully evaluated and their reference lists were examined in order to identify other manuscripts that could be included in the present drug evaluation.
Medical therapy of endometriosis
Circulating estrogens stimulate the growth of endometriotic implants. Furthermore, it known that estradiol (E 2 ) is produced locally by the overexpression of aromatase in the endometriotic implants of all phenotypes of endometriosis [11, 12, 13] . Moreover, also the presence of estrogen and progesterone receptors has been well documented in the three types of endometriosis [14] , including DIE [15] . In addition, endometriotic cells produce several prostaglandins that are involved in the inflammatory state, pelvic pain and neo-angiogenesis of implants [16] .
The currently available medical therapies for endometriosis primarily exert their action by suppressing ovulation and inducing a relatively hypoestrogenic state. Hormonal therapies, particularly progestins and COCs, have been repeatedly demonstrated to be safe, well tolerated and effective in clinical trials, and currently they represent the first-line medical treatment for women affected by this disease [17, 18] . Laparoscopic confirmation of the diagnosis of endometriosis may be advisable prior to administering second-line hormonal treatments, such as gonadotropinreleasing hormone agonists (GnRH-a), which induce suppression of the hypothalamic-pituitaryovary axis [19] . If all these treatments are ineffective, experimental therapies, such aromatase inhibitors, may be considered [20] .
A c c e p t e d M a n u s c r i p t
Progestins
Progestogens acts on endometriotic implants exerting systemic and local effect, so that they aim to induce anovulation and hypoestrogenism causing decidualization and acyclicity of both normal and ectopic endometrium. Firstly, on hypothalamus, they reduce the frequency and increase the amplitude of gonadotropin-releasing hormone (GnRH) pulsatile release, thus leading to a reduction in the secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH). Therefore, the continuous use of progestogens causes suppression of ovarian steroidogenesis with anovulation decreasing serum levels of endogenous ovarian steroids. Moreover, they can locally inhibit inflammatory pathways and response, and provoke apoptosis of endometriotic cells [21] . In particular, it has been demonstrated that they can reduce interleukin (IL)-6, IL-8, and monocyte chemotactic protein (MCP)-1 secretions of endometriotic stromal cells, and cellular proliferation stimulated by tumor necrosis factor-α (TNF-α) [22, 23] . Furthermore, they reduce oxidative stress, inhibits angiogenesis as well as suppress expression of matrix metalloproteinases, which may contribute to the development and to the growth of endometriotic lesions ( Figure 1 ) [12, 24] . All these direct effects and the concomitant hypoestrogenic environment associated with hyperprogestogenic systemic status may be responsible for the decidual transformation and consequent atrophy of the normal endometrium and ectopic implants [25] .
Progestins, synthetic progestogens, are a chemically various group of compounds with a multiplicity of actions on progesterone receptor as well as estrogen, androgen, mineralocorticoid, glucocorticoid and other receptors. These compounds can be divided in three classes ( Figure 2 ):
progesterone derivatives (pregnanes), testosterone derivatives (estranes and gonanes) and spironolactone derivatives. A great variety of progestins, available in different and multiple formulations (Table 1) , have been employed in the management of endometriosis in association with estrogens or alone [17, 26] . However, only progestins belonging to progesterone and testosterone derivatives have been used as monotherapy; while no spironolactone derivate has been tested in this setting.
The drugs have good tolerability profile. The main progestin-related adverse effects (AEs) experienced by patients are spotting and breakthrough bleeding, depression, breast tenderness and fluid retention. These AEs are also the major cause of discontinuation of treatment in these patients [27] .
Currently, among the progestins, only depot medroxyprogesterone acetate (DMPA) and norethindrone acetate (NETA) as monotherapy are approved by the Food and Drug Administration (FDA) for the treatment of endometriosis.
Norethindrone acetate
NETA (17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate) is a synthetic, orally active progestin, derivative of 19-nor-testosterone (estrane, testosterone derivate). It has also weak estrogenic and androgenic properties [28] .
Pharmacokinetic
After oral administration, NETA (5 mg) is completely and rapidly deacetylated to norethindrone (NET) [29] , which generally achieves maximum plasma concentration (C max ) within 2 hours [30] . [33] .
In a patient-preference parallel cohort study, continuous NETA (2.5 mg/day) was compared to surgery for the treatment of 154 patients with endometriosis-associated deep dyspareunia. In the surgery group (51 women), there was a marked improvement of dyspareunia, followed by partial recurrence of pain. In the NETA group (103 patients), pain relief was more gradual but progressive throughout the whole study period. Moreover, at the end of 12 months of follow-up, patients treated with NETA had a greater increase in intercourse frequency per month and had higher satisfaction (59% versus 43%). At 1-year follow-up, NETA had better outcomes than surgery in patients without DIE implants. Moreover, among patients with rectovaginal nodules, NETA showed comparable efficacy [34] . A c c e p t e d M a n u s c r i p t
The presence of intestinal endometriosis was confirmed in all patients who underwent surgery after the end of the treatment (n=13) [35] .
A prospective, non-randomized, open-label study including 40 patients compared the changes in the volume of ovarian endometriotic cysts during 6-month treatment with NETA alone or combined with letrozole. Both treatments significantly decreased the volume of endometriomas; however, the decrease in the volume of endometriomas was higher in patients receiving the double-drug regimen than in those receiving NETA alone. The improvement in pain symptoms was similar in the two study groups. After the discontinuation of treatment, the volume of endometriotic cysts progressively increased and after 6 months it was similar to baseline in both study groups [36] .
In a long-term retrospective cohort study, 103 women with pain symptoms caused by rectovaginal endometriosis received NETA (2.5 mg/day up to 5 mg/day) for a 5-year therapy. Overall, 68.8%
(42/61) of the women who completed the study were satisfied or very satisfied of NETA. Intensity of chronic pelvic pain and deep dyspareunia significantly decreased during treatment (p<.001 versus baseline at 1-and 5-year). Dyschezia improved after 1-year compared to baseline (p=0.008) but it remained stable between first and second year (p=.409). Regarding size of implants, a reduction was observed at RMI in 55.9% (33/59) of women whereas a volumetric increase was observed in 11.9% of them (7/59) [37] .
Recently, a patient preference prospective study demonstrated that NETA (2.5 mg/day) and a 91-day extended-cycle COC (LNG plus EE 150/30 μg for 84 days and EE 10 μg for 7 days) have similar efficacy in treating pain symptoms related to endometriosis [38] . However, the extendedcycle OC caused more unscheduled bleeding than NETA.
Regarding safety-profile of NETA by evaluating the largest series available, among 271 patients the most common AEs experienced were weight gain (n=78, 28.8%), breakthrough bleeding (n=45, 16 .6%) and decreased libido (n=34, 12.5%) [6, 37, 39] .
Cyproterone acetate
Cyproterone acetate (CPA, 6-Chloro-17α-hydroxy-1α,2α-methylenepregna-4,6-diene-3,20-dione acetate) is a synthetic steroid with antiandrogenic and progestinic proprieties (gonane, testosterone derivate) [40] .
Pharmacokinetic
An intra-individual comparison study investigated the PK of CPA in six healthy women. Following oral administration of CPA-14 C (2 mg), administered together with EE (50 pg), the maximum radioactivity in the total plasma volume was 2.0% of the dose. After 24 hours from its administration, 0.63% of the dose was detected in plasma, and the mean CPA-
14
C AUC was 26.7%.
Disposition phase 1 was recognizable in the period between the C max and 12-16 hours after administration and passed with a t 1/2 of 3-4 hours. In the period from 24 hours to day 3, the plasma concentration fell more slowly with a t 1/2 of approximately 2 days [41] . In terms of plasma protein binding, CPA does not bind to SHBG or transcortin and is instead bound exclusively to albumin (93%) [42] . Thus, the terminal t 1/2 of the total activity in plasma was determined as 1.7 days. CPA is almost completely metabolized via the cytochrome P450 isoenzyme CYP3A4, and its main metabolite is 15β-OH-CPA. In the study, its quotient of the elimination urine: faces was 0.5, with mean balances of 88% of the dose [41] .
Clinical efficacy and safety
The use of CPA as monotherapy for the treatment of endometriosis has been investigated only in two studies. A pilot study by Moran et al. on seven women with surgically confirmed endometriosis evaluated the effectiveness of 6-month cyclical CPA (10 mg/day for 20 days, followed by 10 days without medication). The regimen improved dysmenorrhea in all the patients. At second-look laparoscopy, five patients (71%) had minimal endometriosis and two patients (29%) had no evidence of the disease [43] . p=.65). Dysmenorrhea, deep dyspareunia, and non-menstrual pelvic pain scores were substantially reduced and significant improvements in QoL, psychiatric profile, and sexual satisfaction were observed in both treatment groups. Amenorrhea was reached in approximately 66% of women who received CPA and in about 50% of those who received COC. The withdrawal rate was similar in both groups (9 and 6 patients, respectively) [44] .
Regarding safety profile of CPA as monotherapy for endometriosis, in the study by Vercellini et al.
the main AEs experienced were bloating or swelling (n=14, 32%), spotting (n=12, 28%) and weight gain (n=8, 19%). The mean weight gain was 2.4 kg (versus 2.2 kg for COC) whereas there were no significant changes in serum lipid profiles. Moreover, the main AEs that caused CPA discontinuation were bloating (n=1), decreased libido (n=1), depression (n=1), and headache (n=1) [44] .
Desogestrel
DSG (3-Deketo-11-methylene-17α-ethynyl-18-methyl-19-nortestosterone) is a third-generation 19-nortestosterone derivative progestin (gonane, testosterone derivate) [45] . It is commonly used in various formulations for hormonal contraception including combinations with EE, progestin-only pill and subdermal implants [46] .
Pharmacokinetic
After oral administration, the DNG bioavailability is about 76%. It is rapidly absorbed and converted to 3-keto DSG (or etonogestrel, ETN) [47] by hydroxylation and subsequent oxidation.
The conversion occurs fairly rapidly in vivo, with prevalent hepatic metabolism by cytochrome (CYP) P450 and a moderate contribution of the intestinal mucosa [48] . The bio-activation of DSG to ETN has a wide variation between patients, ranging from 40 to 113% of the dose [49] . ETN is responsible for the pharmacological effect, exerting much stronger progestogen activity than the A c c e p t e d M a n u s c r i p t parent compound. During multiple oral administration of DSG (75 µg), the C max of ETN is approximately 640 pg/ml and it is achieved within 2 h. Its steady state is reached after 4 days. ETN is largely bound to serum albumin (58%) and SHBG (38%), and 3.5% remains unbound and bioactive. ETN is subsequently metabolized to polar derivatives in the liver. The ETN t 1/2 is about 30 h, with no difference between single and multiple oral doses [50] ; the drug is predominantly (~60%) excreted via urine, and only about 35% is excreted via feces [51] .
Clinical efficacy and safety
In the first study reported, continuous oral DSG (75 μg/day) was compared to COC (EE 20 μg + DSG 150 μg /day) for the treatment of 40 patients with stage I-II endometriosis. At 6-months of follow-up, pelvic pain improved without difference between the two study arms. Moreover, breakthrough bleeding (20%) was the main AE reported in the DSG group [52] .
In an open-label prospective trial, the combinatory regimen of oral DSG and an aromatase inhibitor (letrozole, 2.5 mg/day) was studied in the 6-month treatment of 12 patients with persistent endometriosis-related (stage IV) pelvic pain, not responding to previous surgical and medical therapies. None of the patients completed the treatment course because of the development of functional ovarian cysts; the median length of treatment of 84 days (range . This AE should be ascribed to the aromatase inhibitor. In fact, this drug blocks the conversion of androgens to estrogens in ovarian granulosa cells, with a consequent reduction of the negative feedback at the pituitary-hypothalamus level, and therefore, increase of serum FSH levels that promoted the ovarian follicles growth. Although the authors chose to combine letrozole with DSG to inhibit effectively ovulation, the progestin did not prevent the development of functional ovarian cysts. During the treatment period, all the patients had significant improvements in dyspareunia and chronic pelvic pain. The main AEs in both groups were abnormal bleeding (75%), weight gain (50%) and abdominal bloating (42%) [53] .
In 2014, a patient preference trial compared the contraceptive vaginal ring (EE 15 μg + ENG 120 μg), administered cyclically, with oral DSG (75 μg/day) for the treatment of women with A c c e p t e d M a n u s c r i p t symptomatic rectovaginal endometriosis. In this trial, 60 women received DSG and 83 women the vaginal ring. At the end of the 12-months of treatment, the rate of satisfied women was higher in the DSG group (61.7% versus 36.1%). There was no difference in the withdrawal rate between the two study groups. Moreover, the two treatments caused a similar disease volume size reduction.
Interestingly, gastrointestinal symptoms, chronic pelvic pain, and deep dyspareunia improved more in patients receiving DSG [54] .
In another patient preference study, oral DSG (75 μg/day) and cyclic COC (EE 20 μg + DSG 150 μg) were administered to 74 women with symptomatic rectovaginal implants and migraine without aura [55] , which has been demonstrated to be often associated to endometriosis [56] . Both treatments were equally effective in decreasing endometriosis-related pain. After 6 months of treatment, the withdrawal rate was higher in the COC group (24.4% versus 11.3%), but the number of days with bleeding was higher in the DSG group (5.1 versus 3.2 days). The satisfaction rate was higher for patients receiving DSG (61.2% versus 37.8%), which showed also a significant improvement in QoL. In addition, the severity and number of migraine attacks were significantly different between baseline and the end of treatment in the DSG group (P<.001) but not in COC group (P=.078). Regarding available safety data on DSG as monotherapy for endometriosis, this latter trial demonstrated that among 31 patients, the most common AEs were acne (3.2%), nausea (3.2%), breast pain (6.4% in the POP group) and weight gain (6.4%) [55] . 
Etonogestrel-subdermal implant

Pharmacokinetic
A c c e p t e d M a n u s c r i p t 
Clinical efficacy and safety
Few data are available on the use of the ENG-subdermal implant for the treatment of women with endometriosis ( Table 2 ).
In an uncontrolled open clinical trial, the ENG-subdermal implant efficacy was evaluated in 50 symptomatic women with surgically confirmed endometriosis. The authors reported an improvement of pain levels and a high satisfaction rate (80%). After a short follow-up (12 weeks), women had spotting (26%) and intermestrual bleeding (4%) [60] .
In a RTC, Walch et al. compared the efficacy of ENG-subdermal implant (n = 21 patients) to DMPA-SC (n = 20) for the treatment of pain related to endometriosis. After 6-months of treatment, the mean reduction in pain was 68% in the ENG subdermal implant group and 53% in the DMPA-SC group. The overall degree of satisfied plus very satisfied subjects was almost identical in both groups (57% in the ENG-subdermal implant group versus 58% in the DMPA group), and, at 1-year follow-up, also the improvement in pain intensity was equivalent [61] .
Safety data from the trial by Walch et al demonstrated that the most common AEs in patients receiving ENG-subdermal implant were breast tenderness (24%) and libido decrease (24%).
Moreover, there was a lower withdrawal rate in the ENG group (n=4, 19%) compared to the DMPA-SC group (n=7, 35%). The main cause of ENG-discontinuation was unbearable bleeding A c c e p t e d M a n u s c r i p t irregularities (n=2, 50%) [61] .
The effect of ENG-subdermal implant on bone mineral density (BMD) is controversial: in a prospective study, in which it was compared to non-hormone-medicated intrauterine device (IUD), similar changes in BMD were demonstrated from baseline to the end of treatment. In particular, the clinically significant mean decrease of z-score -1 was not nearly reached at all the anatomical sites of the body measured in both groups [62] . In contrast, another group reported a significantly decrease of -5.90% (P<0.001) on forearm BMD after 18 months from ENG-subdermal implant insertion [63] .
Medroxyprogesterone acetate
Medroxyprogesterone acetate (MPA, 6α-Methyl-17α-hydroxyprogesterone) is a synthetic derivative of 17-hydroxyprogesterone (pregnane, progesterone derivative). MPA is available as oral formulation or depot formulation, which can be administered intramuscularly (DMPA-M) [64] and subcutaneously (DMPA-SC) every 3 months [65] . This progestin has also anti-androgenic and strong anti-glucocorticoid effect (thirty times higher than either DNG or NETA) [66].
Pharmacokinetic
MPA ( A c c e p t e d M a n u s c r i p t demonstrated that the administration of MPA (100 mg/day) for 6 months is as effective as danazol in the treatment of pain both after diagnostic laparoscopy [73] and after surgical excision of endometriosis [74] . One prospective double-blind RCT, involving 48 women with surgical diagnosis of endometriosis, compared MPA (45 mg/day) with naferelin (400 µg intranasal) for treating pain. Patients were treated for 6 months and followed for 1 year. There was a significant reduction in the severity of pain symptoms during the study, without any significant difference between the study groups [75] . These findings are in contrast to a prospective, double-blind RCT involving 100 infertile women (only 25% of them had mild-severe pelvic pain) with a surgical diagnosis of endometriosis, which compared the efficacy of 3-month administration of MPA (50 mg/day) with placebo [76] .
From data extracted and analyzed from RTCs, a Cochrane review reported that MPA (100 mg daily) appears more effective in reducing all symptoms up to 12 months of follow-up (MD -0.70, 95% CI -8.61 to -5.39; P < 0.00001) compared with placebo. Moreover, patients receiving MPA had more cases of acne and edema [77] .
DMPA has been investigated in few clinical trials for the treatment of women with endometriosis (Table 2 A c c e p t e d M a n u s c r i p t significant decrease in all symptoms scores was reported in both study arms without significant differences. The main AEs in the DMPA-M group were spotting (26%), bloating (25%) and weight gain (21%). In addition, the median time to return of regular menstrual flow in women who received DMPA-M was 7 months. In both arms, there was a significant reduction in high-density lipoprotein cholesterol [78] .
A RCT compared a 3-years regimen of DMPA-M (150 mg/3 months) with the levonogestrelreleasing intrauterine system (LNG-IUD) in 30 patients after conservative surgery for endometriosis. Both treatments were effective in the management of pain symptoms, and the only domains where no amelioration was observed were dyspareunia and urinary/bowel symptoms. At TVS, no recurrence of lesions was detected in both groups. The dropout rate was higher in the DMPA-M group (53% versus 13%), and the two most common causes of discontinuation among the eight patients that interrupted DMPA-M were prolonged vaginal spotting (n=3, 37.3%) and significant bone loss over the lumbar spine (n=2, 25%) [79] .
In two large RTCs, Crosignani et al. and Schalff et al. compared DMPA-SC (104 mg/0.65 ml) with leuprolide acetate (given every 3 months for 6 months). At 12-months of follow-up, DMPA-SC was statistically equivalent to GnRH-a in reducing pain symptoms. Moreover, significant improvements in QoL occurred in both treatment groups [80, 81] . Interestingly, in the study by Crosignani et al.
patients who received DMPA-SC reported a significant amelioration in their sexual relationship after 6 months of treatment [80] .
One of major sources of concerns regarding the continuous DMPA use is the breakthrough bleeding, the primary reason for its discontinuation among women using it for contraception [82] .
Moreover, pooled analysis from three Phase III contraceptive trials demonstrated that the therapy with DMPA (SC and M) causes gained weight [83, 84] . A further concern on DMPA use is the loss of BMD, which may increase the risk of fracture [85] . For this reason, in 2004 the FDA published a 'black box warning', suggesting physicians its administration only if the other methods were unsuitable or unacceptable, limiting the maximum use to 2 years [86] .
Dienogest
Dienogest (DNG, 17α-Cyanomethyl-δ9-19-nortestosterone) is a fourth-generation selective progestin (estrane, testosterone derivate). It has minimal androgenic, estrogenic, glucocorticoid or mineralocorticoid activity [87] .
Pharmacokinetic
After a single dose, DNG (2 mg) has high bioavailability (<90%) [88] , reaching a mean C max of 51.7 ng/mL within 1.0 h (range of 0.7-4 h). Its mean AUC 0-24h is 503 ng·h/mL. 90% of DNG binds to albumin, whereas only 10% is present in plasma in the free form. 
Clinical efficacy and safety
Several RTCs have investigated the use of DNG for the treatment of endometriosis (Table 3 ) [91] .
A systematic review showed that DNG (2 mg/day) is superior to placebo in reducing pelvic pain (27.4 versus 15.1 mm, P <.0001) and as effective as GnRH-a in controlling symptoms associated with endometriosis. Moreover, DNG is effective in reducing endometriotic lesions (11.4 ± 1.71-3.6 ± 0.95, P <.001) [92] . Concerning the use of DNG as maintenance therapy after GnRH-a to treat pelvic pain associated with endometriosis, Kitawaki et al., in a prospective nonrandomized clinical trial, showed that long-term administration of DNG following GnRH-a therapy prolongs the relief of pelvic pain while reducing the amount of irregular uterine bleeding [93] .
In a 6-months double-blind multicenter RTC, DNG (2 mg/day) efficacy and safety were evaluated in 255 Chinese patients with laparoscopically diagnosed endometriosis. At baseline, they had an endometriosis-associated pelvic pain (EAPP) score ≥30 mm on a 0-100 mm visual analog scale (VAS). After the end of treatment, DNG obtained a higher mean reduction in EAPP score than placebo (-24.54 mm; 95% CI -29.93 to -19.15; p < 0.0001). Moreover, DNG was well tolerated, although the incidence of drug-related AEs was higher to that of patients receiving placebo (29.4% vs 10.1%), with intensity of AEs mild-to-moderate in most women. Anyway, the AE-related discontinuation rate for both groups was comparable (1.6% vs 0.8%) [94] . DNG has also been used for the conservative treatment of bladder endometriosis [96] . In recent pilot study including six women with bladder endometriotic lesions, the administration of DNG (2 mg/day) for 12 months improved pain symptoms. Furthermore, urinary symptoms disappeared in all the patients and there was a significant size decrease of bladder nodules at TVS after 3 and 12 months of treatment [97] . In a prospective study, Leonardo-Pinto et al. Vercellini et al., through a before-after study design, compared NETA and DNG for the treatment of women with endometriosis. Both drugs caused pain relief and improvement of psychological status, sexual functioning, and health-related QoL of the patients. After 6 months, the proportion of satisfied plus very satisfied women was almost identical between the two study groups (71% in NETA group versus 72% in DNG group). After DNG implementation, the absolute risk reduction in the occurrence of any AE compared to NETA was 13.9% Thus, DNG was better tolerated than NETA, but the much higher cost limited its acceptance by the women [99] . Surprisingly, up to now no RCT compared DNG with COCs or other progestins, the first-line therapies most commonly used for the treatment of endometriosis [91] .
A recent study has evaluated the safety and tolerability of DNG among patients with endometriosisassociated pain by pooling data from four randomized, controlled, European studies. Overall, 332
women were treated with DNG (2 mg/day) for study periods ranging between 12 weeks and 65
A c c e p t e d M a n u s c r i p t weeks. The most common drug-related AEs were headache, breast discomfort, depressed mood, and acne, occurring in 9.0%, 5.4%, 5.1%, and 5.1% of women, respectively [100] .
The effect of DNG on BMD is controversial. In a comparative study, Lee et 
Levonorgestrel-releasing intrauterine device
Levonogestrel (LNG, 17α-Ethynyl-18-methyl-19-nortestosterone) is a synthetic second-generation progestin chemically derived from 19-nortestosterone (gonane, testosterone derivate). It is six times more potent than progesterone, but also has strong androgenic properties. Most of the interest for LNG in the treatment of endometriosis is focused on the LNG-releasing intrauterine device (LNG-IUD) [104] .
Pharmacokinetic
LNG-IUD (52 mg) releases low doses of LNG directly into the uterine cavity. Its initial release rate is approximately 20 µ/day over the first 3 months (day 0-90), it is reduced to approximately 18 µ/day after 1 year and then decreases progressively to approximately 10 µ/day after 5 years [105] .
A stable serum LNG concentration of approximately 150-200 pg/mL occurs after the first few weeks, following insertion of LNG-IUD [106] . LNG concentrations at 12-, 24-and 60 months have been estimated to be 180 pg/mL, 192 pg/mL, and 159 pg/mL, respectively. When released, LNG has a V D of approximately 1.8 L/kg, and it is about 98-99% bound to serum proteins (47.5% to A c c e p t e d M a n u s c r i p t SHBG) [66] . The excretion of LNG and its phase I metabolites is primarily as glucuronide conjugates via urine in about 45% and via feces in about 32% of total [105] .
Clinical efficacy and safety
The most important mechanism of action of the LNG-IUD is through its local suppressive action on the endometrium. Amenorrhea develops in approximately 20% of LNG-IUD users by one year [105] . In patients with endometriosis, the LNG-IUD decreases the expression of glandular and stromal estrogen (α and β) and progesterone receptors in the ectopic endometrium and, thus, induces glandular atrophy and decidualization of the stroma [107, 108] .
A pilot-study including 11 women with symptoms caused by rectovaginal endometriosis demonstrated that the use of the LNG-IUD improved the severity of all pain symptoms, including deep dyspareunia and dyschezia, at 1-year follow-up. Moreover, the LNG-IUD succeeded in decreasing the rectovaginal lesions size, evaluated by transrectal ultrasound and TVS [109] .
Several RTCs have investigated the use of LNG-IUD for the treatment of endometriosis (Table 4) .
Chwalisz et al. compared the efficacy of LNG-IUD and depot GnRH-a (leuprolide 3.75 mg) in 82 women with endometriosis-related pain over a period of six months. At 6 months of follow-up, both treatments were similarly effective in improving chronic pelvic pain, demonstrating a six-point decrease from baseline in the VAS pain score. At the end of the study, 13% (n = 5) of patients in the LNG-IUD group and the 14% (n = 6) of those in the leuprolide group failed to reach a VAS pain score of less than three. Furthermore, no difference was observed between groups with reference to improvement in QoL [110] . In a meta-analysis including five RCTs, the comparative evaluation of LNG-IUD and GnRH-a demonstrated that both regimens succeed in reducing pain, as well as CA125 serum levels and the American Society of Reproductive Medicine staging scores.
Irregular bleeding, simple ovarian cysts and one-sided lower abdominal pain occurred more commonly in patients receiving the LNG-IUD (P<.03), whereas those receiving GnRH-a experienced more hypo-estrogenic AEs (P<.05) [111] .
The long-term therapy with LNG-IUD has been evaluated in a retrospective study by Lockhat et al., A c c e p t e d M a n u s c r i p t in which it resulted efficacious in improving symptoms throughout a 3-year study period [112] .
These results are in line with those obtained in a RCT that compared the 36-month use of LNG-IUD with DMPA-M in 30 patients with moderate and severe endometriosis. The mean pain score evaluated at VAS was significantly reduced by the next visit at three months after insertion of LNG-IUS (P <.02) or starting of DMPA-M injection (P <.002), and the effect was maintained all through the study period as long as the therapy was continued. Anyway, there was no significant specific change in dyspareunia and urinary and bowel symptoms in both groups of patients [79] .
The LNG-IUD has been used for the post-surgical prevention of endometrioma recurrence. In their randomized prospective studies, Tanmahasamut The number of recurrent endometrioma requiring a second surgery or a hormonal treatment was significantly higher in the expectant management group (8/40, 20% versus 1/40, 2.5%) [117] .
Regarding the safety profile of LNG-IUD as post-surgical monotherapy for endometriosis, in the two largest RTC evaluable for drug-related AEs, among 48 patients, the most common were oily skin (n=20, 41.6%), weight gain (n=19, 39.5%), breast tenderness (n=18, 37.5%) and irregular bleeding (n=17, 35.4%) [113, 118] .
Conclusion
Expert opinion
Currently, the medical choices for symptomatic endometriosis are based on patient preferences and treatment goals as well as the efficacy and the safety-profile, the desire of contraception, the cost, and the route of administration of the drugs. As endometriosis is a chronic and recurrent disorder, a long-term medical therapy should be well-tolerated, have only limited AEs and be cost-effective [26] . However, hormonal treatments do not eradicate the disease but allow to obtain an effective control of pain symptoms in the 80-90% of cases. In line with this, recurrence of symptoms is frequent after discontinuation of treatment [119] . While progestins can decrease the volume of endometriomas [36] , there is no evidence that the medical therapy can prevent the progression of DIE. Therefore, patients undergoing long-term hormonal treatment for endometriosis-related pain need a follow-up by ultrasonography to timely detect the progression of DIE causing bowel or ureteral stenosis [120] .
If COCs have been used for decades as the first-line treatment for symptomatic endometriosis, progestins are increasingly and successfully employed as monotherapy [10] . These drugs are often started empirically without a surgical diagnosis of endometriosis and are particular efficacious in women suffering dysmenorrhea and menstrual-related symptoms.
Progestins cause a lower increase in the thrombotic risk compared with COCs and are better tolerated by patients suffering migraine [121] . A potential disadvantage for the use of progestins in A c c e p t e d M a n u s c r i p t women desiring contraception is that only three of them (DSG, ENG-subdermal implant and LNG-IUD) are approved as contraceptive. Overall, medical therapy with progestins enables satisfactory long-term pain control in around two-thirds of symptomatic women [2] . The imbalance of ER and PR subtypes or of adhesion molecules imbalance might contribute to the mechanisms involved in the progesterone resistance of patients' population refractory to these hormonal therapies. As no biomarkers for progestin resistance has been proposed, a dynamic monitoring of response to progestins is warranted in order to switch to other options or to discuss in the appropriate time the surgical option [122] .
There is lack of data on the specific effects of progestins use on the breast, the mood and cardiovascular system. A French report on contraception with progestins showed that it has never been demonstrated that their use is associated with an increased risk of breast cancer. Moreover, there is no evidence for considering the progestin-only contraception as a risk factor for fractures.
Also, the impact of long-term systemic progestins use on BMD is controversial [27] .
Data from clinical trials for the treatment of endometriosis suggested that progestins are well tolerated when administered in a long-term treatment. Data from clinical trials suggest that the most frequent AEs reported by the patients are spotting and breakthrough bleeding, weight gain, breast tenderness and depression [17, 18] . These AEs are also the major cause of discontinuation of treatment.
Currently, randomized, controlled studies support the use of oral progestin-only treatment for controlling pelvic pain associated with endometriosis. Almost none of these trials is double-blinded.
A Cochrane review [77] It is well known that progestins can induce decidualization and eventual atrophy of endometriotic implants and that they improve women' pain, but there is a common misconception that all progestins have similar mechanisms of action and PK parameters. Moreover, it is growing the evidence that progestins, in addition to their systemic effect on estrogen production, may also exert an immune-suppressive influence on endometriotic lesions at local disease sites [23] and furthermore that this influence is not uniform for all progestins, depending from the biological activity.
In fact, each one has a distinct biological effect influenced by pharmacodynamics affinity not only for PR, but also for other steroid receptors, such as estrogen, androgen, and glucocorticoid. Although FDA licensed oral NETA at 5 mg/day, several studies reported excellent outcomes using only 2.5 mg/day. Its lower dosage increases tolerability, reducing AEs, and limits the negative impact on serum cholesterol values. NETA exerts directly an activity on estrogen receptors -α and -β, and it is a substrate for aromatase, being converted in the liver to a small extent (0.20-0.33%) to A c c e p t e d M a n u s c r i p t potent EE [32] . For these reasons, unlike most other progestins, NETA has some estrogenic activity, which may be responsible for a positive effect on BMD. NETA is efficacious in the longterm control of endometriosis-related pain [37] ; however, being not able to induce a significant regression of implants, it does not represent a definitive curative treatment for this disease.
DNG is a new fourth-generation selective progestin. As reported in several clinical trials, DNG showed efficacy and good tolerability at doses of 2-4 mg/ day in continuous administration for 3-24 months in patients with endometriosis. Although DNG seems to be at least equally effective and better tolerated than NETA [95, 99] , the much higher cost limits its acceptance by patients. A recent review evaluated the PK characteristics of DNG with other progestins derivatives, such as NETA, LNG and gestodene. This comparison showed that DNG is one of few synthetic progestogens that does not bind to SHBG, that has no influence on the PK of testosterone and has no androgenic effects. Moreover, DNG has the highest free-unbounded fraction in the plasma (approximately 10%). The high circulating levels of free DNG explain the wide penetration of the molecule in several tissues [66] .
An innovative approach to improve the use of progestins in endometriosis is the development of long-acting progestogen systems. In the Cochrane review [77] , it has been reported the absence of benefit after depot administration of progestins versus other treatments (low dose COCs or leuprolide acetate). Anyway, only two comparative trials on DMPA were included in this review, and, further studies are needed to draw a definitive conclusion. One of major sources of concerns regarding continuous DMPA use is the decrease of BMD. However, the reversibility of the negative impact of DMPA on BMD toward or to baseline values within 2 years after discontinuation has been demonstrated in several studies [123, 124, 125] and the data regarding the risk of an eventual fracture are controversial [126, 127, 128] . Furthermore, DMPA is often accompanied by unintentional weight gain, loss of libido, which might adversely affect a woman's QoL and preclude long-term use. Among long-acting progestogen systems, ENG-subdermal implant could be preferable to DMPA in patients with preexisting high BMI and impaired metabolic profiles for its A c c e p t e d M a n u s c r i p t lower impact on metabolic profile. Furthermore, the ENG-subdermal implant is particularly useful for patients desiring contraception. The main disadvantage of the depot formulation is the impossibility to interrupt treatment in the event of AEs. In fact, in some patients, the irregular bleeding caused by depot progestins may be prolonged, repeated and difficult to correct.
One of the best candidates for the long-term treatment of endometriosis is the LNG-IUD. In comparison with systemic administration, the local release of a drug should theoretically provide a similar or improved efficacy, particularly evident on the local target organ, with reduced systemic AEs. LNG-IUD is particularly suitable for patients with concomitant adenomyosis [129] , and who do not want to conceive or wish to postpone pregnancy, whose main symptom is dysmenorrhea, and who do not tolerate progestins administered systemically. Moreover, the LNG-IUD can be inserted M a n u s c r i p t Tables   Table 1 . 
